We are delighted to announce that the Annals of Oncology Impact Factor has risen to 9.269 . Annals of Oncology now has a five year Impact Factor of 7.828 and is ranked 11th in the Oncology category of the Journal Citation Reports®.
We would like to take this opportunity to thank all who have contributed to the journal’s high ranking, helping us to remain highly placed, which enables your work to achieve global readership and high citations in the field.
Take a look at the top 15 most highly cited articles that contributed to the rise in Impact Factor.
Find out more about the global impact of the journal.
Top 15 most highly cited articles
1. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi, S. Michiels, R. Salgado, et al.
2. European cancer mortality predictions for the year 2014
M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia and E. Negri.
3. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A.S. Coates, E.P. Winer, A. Goldhirsch, et al.
4. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
D.S.M. Chan, A.R. Vieira, D. Aune, et al.
5. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso, A. Costa, L. Norton, et al.
6. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann, J. Rodon, A. Prat, et al.
7. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
J.-M. Lee, J.A. Lederman, and E.C. Kohn
8. Estimates of benefits and harms of prophylactic use of aspirin in the general population
J. Cuzick, M.A. Thorat, C. Bosetti, et al.
9. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
J.Y. Douillard, S. Siena, J. Cassidy, et al.
10. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart, G.N. Hortobagyi, M. Campone, et al.
11. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy verses chemoradiotherapy alone as treatment of unresectable head and neck cancer
R. Hitt, J.J. Grau, A. López-Pousa, et al.
12. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado, C. Denkert, S. Demaria
13. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
K. Azuma, K. Ota, A. Kawahara, et al.
14. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
S.-H. I. Ou, P. A. Jänne, C.H. Bartlett, et al.
15. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M.V. Dieci, C. Criscitiello, A. Goubar, et al.
Impact and influence on a global scale
With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape.
Professor Soria, the Editor-in-chief of Annals of Oncology thanks the research community and summarises the key reasons why he thinks you should publish in the journal.
Want to find out more?
Stay up-to-date with the latest research with email table of contents alerts.
Access content when and where you want it with the